How much is a reg­u­la­to­ry short­cut worth?

The cost of a pri­or­i­ty re­view vouch­er, which short­ens the FDA’s stan­dard re­view time by about four months...

Japan's Sh­iono­gi on Mon­day said it won FDA ap­provalfor its oral an­tivi­ral to pre­vent Covid‑19 in adults and chil­dren old­er than 12 years who...

A new method of CRISPR-based gene edit­ing shows promise in cur­tail­ing chron­ic he­pati­tis B in­fec­tions. Its twist is to si­lence dis­ease-caus­ing genes with­out al­ter­ing the...

Two ple­nar­ies re­lat­ed to Lil­ly:Re­searchers de­tailed find­ings from an in­ves­ti­ga­tor-spon­sored tri­al us­ing Lil­ly’s CDK4/6 in­hibitor Verzenio in a rare can­cer called ded­if­fer­en­ti­at­ed li­posar­co­ma, show­ing...

Servi­er will pick up the mus­cu­lar dy­s­tro­phy busi­ness from Edge­wise Ther­a­peu­tics for $1.55 bil­lion up­front, giv­ing the French phar­ma com­pa­ny ac­cess to an ex­per­i­men­tal neu­ro­mus­cu­lar...